ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients

被引：0

作者：

Saam A. Mojtahed

Nicole R. Boyer

Saieesh A. Rao

Thomas F. Gajewski

Jennifer Tseng

Kiran K. Turaga

机构：

[1] University of Chicago,Pritzker School of Medicine, Division of Biological Sciences

[2] University of Chicago,Center for Health and the Social Sciences

[3] University of Chicago,Department of Pathology, Division of Biological Sciences

[4] University of Chicago,Department of Surgery, Division of Biological Sciences

来源：

Annals of Surgical Oncology | 2021年 / 28卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：576 / 576

共 50 条

[21] ASO Visual Abstract: Adjuvant Therapy for Stage III Melanoma without Immediate Completion Lymph Node Dissection
Robert J. Torphy
Chloe Friedman
Felix Ho
Laura D. Leonard
Daniel Thieu
Karl D. Lewis
Theresa M. Medina
William A. Robinson
Rene C. Gonzalez
Camille L. Stewart
Nicole Kounalakis
Martin D. McCarter
Ana Gleisner
Annals of Surgical Oncology, 2021, 28 : 738 - 739
[22] ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Surgery for Patients with Clinical Stage II and III Esophageal Squamous Cell Carcinoma-A Cost-Effectiveness Analysis
Gao, Xing
Wen, Yu-Wen
van Lanschot, Joseph Jan Baptist
Chao, Yin-Kai
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (06) : 3656 - 3657
[23] ASO Visual Abstract: Adjuvant Therapy for Stage III Melanoma without Immediate Completion Lymph Node Dissection
Torphy, Robert J.
Friedman, Chloe
Ho, Felix
Leonard, Laura D.
Thieu, Daniel
Lewis, Karl D.
Medina, Theresa M.
Robinson, William A.
Gonzalez, Rene C.
Stewart, Camille L.
Kounalakis, Nicole
McCarter, Martin D.
Gleisner, Ana
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 738 - 739
[24] Cost-effectiveness of human interferon-alpha as adjuvant treatment for patients with resected cutaneous malignant melanoma in stage IIB & III
Kasteng, F.
Stadler, R.
Wagenius, G.
Lundkvist, J.
VALUE IN HEALTH, 2007, 10 (06) : A330 - A330
[25] Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
González-Larriba, JL
Serrano, S
Alvarez-Mon, M
Camacho, F
Casado, MA
Díaz-Pérez, JL
Díaz-Rubio, E
Fosbrook, L
Guillem, V
López-López, JJ
Moreno-Nogueira, JA
Toribio, J
EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2344 - 2352
[26] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Bensimon, Arielle G.
Zhou, Zheng-Yi
Jenkins, Madeline
Song, Yan
Gao, Wei
Signorovitch, James
Krepler, Clemens
Liu, Frank Xiaoqing
Wang, Jingshu
Aguiar-Ibanez, Raquel
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
[27] Cost-Effectiveness of Aspirin Adjuvant Therapy in Early Stage Colorectal Cancer in Older Patients
Soon, Swee Sung
Chia, Whay-Kuang
Chan, Mun-ling Sarah
Ho, Gwo Fuang
Jian, Xiao
Deng, Yan Hong
Tan, Chuen-Seng
Sharma, Atul
Segelov, Eva
Mehta, Shaesta
Ali, Raghib
Toh, Han-Chong
Wee, Hwee-Lin
PLOS ONE, 2014, 9 (09):
[28] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
Salans, Mia
Courtney, Patrick Travis
Yip, Anthony
Murphy, James D.
CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
[29] Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma
Schadendorf, Dirk
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ji, Ran
Aimone, Paola
Manson, Stephanie
Kefford, Richard
Dummer, Reinhard
Kirkwood, John M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
Li, Wenqian
Guo, Hanfei
Li, Lingyu
Cui, Jiuwei
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →